OCUGEN INC (OCGN) Stock Price & Overview
NASDAQ:OCGN • US67577C1053
Current stock price
The current stock price of OCGN is 1.79 USD. Today OCGN is up by 1.7%. In the past month the price decreased by -24.79%. In the past year, price increased by 154.93%.
OCGN Key Statistics
- Market Cap
- 586.941M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.23
- Dividend Yield
- N/A
OCGN Stock Performance
OCGN Stock Chart
OCGN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to OCGN. When comparing the yearly performance of all stocks, OCGN is one of the better performing stocks in the market, outperforming 94.74% of all stocks.
OCGN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OCGN. Both the profitability and financial health of OCGN have multiple concerns.
OCGN Earnings
On March 4, 2026 OCGN reported an EPS of -0.06 and a revenue of -193.00K. The company missed EPS expectations (-1.42% surprise) and missed revenue expectations (-122% surprise).
OCGN Forecast & Estimates
13 analysts have analysed OCGN and the average price target is 11.37 USD. This implies a price increase of 534.96% is expected in the next year compared to the current price of 1.79.
For the next year, analysts expect an EPS growth of 1.17% and a revenue growth -60.02% for OCGN
OCGN Groups
Sector & Classification
OCGN Financial Highlights
Over the last trailing twelve months OCGN reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS decreased by -21.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.15% | ||
| ROE | -1812.06% | ||
| Debt/Equity | 8.04 |
OCGN Ownership
OCGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.92 | 367.796B | ||
| AMGN | AMGEN INC | 15.32 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.73 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.59 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.79 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.94 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.34 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OCGN
Company Profile
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 116 full-time employees. The company went IPO on 2014-12-03. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. The company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. The company is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Company Info
IPO: 2014-12-03
OCUGEN INC
11 Great Valley Parkway
Malvern PENNSYLVANIA 19355 US
CEO: Shankar Musunuri
Employees: 116
Phone: 13026587581
OCUGEN INC / OCGN FAQ
What does OCGN do?
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 116 full-time employees. The company went IPO on 2014-12-03. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. The company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. The company is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
What is the current price of OCGN stock?
The current stock price of OCGN is 1.79 USD. The price increased by 1.7% in the last trading session.
Does OCUGEN INC pay dividends?
OCGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of OCGN stock?
OCGN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about OCUGEN INC (OCGN) stock?
13 analysts have analysed OCGN and the average price target is 11.37 USD. This implies a price increase of 534.96% is expected in the next year compared to the current price of 1.79.
What is the Price/Earnings (PE) ratio of OCUGEN INC (OCGN)?
OCUGEN INC (OCGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.23).
What is the outstanding short interest for OCUGEN INC?
The outstanding short interest for OCUGEN INC (OCGN) is 16.39% of its float.